Chiara Rapinesi1,2, Georgios D Kotzalidis3,4, Lorenzo Mazzarini1,2,5, Roberto Brugnoli1,2, Stefano Ferracuti1,2,6, Sergio De Filippis1,2,7, Ilaria Cuomo1,2,8, Gloria Giordano1,2,7, Antonio Del Casale1,2, Gloria Angeletti1,2, Gabriele Sani1,2,9, Paolo Girardi1,2,5,9. 1. Neurosciences, Mental Health, and Sensory Organs (NESMOS) Department, Faculty of Medicine and Psychology, Sapienza University, Rome, Italy. 2. Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy. 3. Neurosciences, Mental Health, and Sensory Organs (NESMOS) Department, Faculty of Medicine and Psychology, Sapienza University, Rome, Italy. giorgio.kotzalidis@uniroma1.it. 4. Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy. giorgio.kotzalidis@uniroma1.it. 5. Salvator Mundi International Hospital-UPMC, Rome, Italy. 6. Department of Human Neuroscience, Sapienza University, Rome, Italy. 7. Department of Neuropsychiatry, Villa von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Rome, Italy. 8. Regina Cœli Penitentiary, RM1, Rome, Italy. 9. Lucio Bini Center, Aretæus Onlus, Rome, Italy.
Abstract
BACKGROUND: Several second-generation antipsychotics (SGAs) are available in long-acting injectable (LAI) formulations. OBJECTIVE: To systematically review the effects of the two formulations, Monohydrate and Lauroxil, of Aripiprazole LAI in patients with schizophrenia and bipolar disorder during an acute episode or during maintenance treatment. METHODS: On September 18, 2018, we adopted the following search strategy: (aripiprazole OR OPC-14597 OR Abilify) AND (long-acting OR depot OR LAI OR once monthly OR prolonged release OR monohydrate OR lauroxil) on PubMed, Cochrane, Scopus, CINAHL, PsycINFO, and Web of Science to identify randomised controlled trials. Furthermore, we searched the ClinicalTrials.gov site for possible additional studies. RESULTS: We included 28 papers dealing with randomised assignment of aripiprazole LAI formulations in schizophrenia and bipolar disorder in survival studies after stabilisation, in acute studies, and in head-to-head comparisons. Both monohydrate and lauroxil formulations reduced relapses/recurrences with respect to comparators (placebo or 50 mg once-monthly monohydrate) and improved symptomatology in acute schizophrenia. LIMITATIONS: Only a small number of studies were included in our review, with widely overlapping samples. While a high proportion of studies were wholly or partly industry-sponsored, their outcomes do not appear to have been affected. CONCLUSION: Aripiprazole LAI may to be efficacious in reducing relapse of schizophrenia and bipolar disorder in the long term in stabilised patients and in improving symptoms of schizophrenia during its acute phase, with both monohydrate and lauroxil formulations showing efficacy.
BACKGROUND: Several second-generation antipsychotics (SGAs) are available in long-acting injectable (LAI) formulations. OBJECTIVE: To systematically review the effects of the two formulations, Monohydrate and Lauroxil, of Aripiprazole LAI in patients with schizophrenia and bipolar disorder during an acute episode or during maintenance treatment. METHODS: On September 18, 2018, we adopted the following search strategy: (aripiprazole OR OPC-14597 OR Abilify) AND (long-acting OR depot OR LAI OR once monthly OR prolonged release OR monohydrate OR lauroxil) on PubMed, Cochrane, Scopus, CINAHL, PsycINFO, and Web of Science to identify randomised controlled trials. Furthermore, we searched the ClinicalTrials.gov site for possible additional studies. RESULTS: We included 28 papers dealing with randomised assignment of aripiprazole LAI formulations in schizophrenia and bipolar disorder in survival studies after stabilisation, in acute studies, and in head-to-head comparisons. Both monohydrate and lauroxil formulations reduced relapses/recurrences with respect to comparators (placebo or 50 mg once-monthly monohydrate) and improved symptomatology in acute schizophrenia. LIMITATIONS: Only a small number of studies were included in our review, with widely overlapping samples. While a high proportion of studies were wholly or partly industry-sponsored, their outcomes do not appear to have been affected. CONCLUSION:Aripiprazole LAI may to be efficacious in reducing relapse of schizophrenia and bipolar disorder in the long term in stabilised patients and in improving symptoms of schizophrenia during its acute phase, with both monohydrate and lauroxil formulations showing efficacy.
Authors: Suresh Mallikaarjun; John M Kane; Patricia Bricmont; Robert McQuade; William Carson; Raymond Sanchez; Robert A Forbes; W Wolfgang Fleischhacker Journal: Schizophr Res Date: 2013-07-23 Impact factor: 4.939
Authors: Claudia Leucht; Stephan Heres; John M Kane; Werner Kissling; John M Davis; Stefan Leucht Journal: Schizophr Res Date: 2011-01-22 Impact factor: 4.939
Authors: John M Kane; Raymond Sanchez; Pamela P Perry; Na Jin; Brian R Johnson; Robert A Forbes; Robert D McQuade; William H Carson; W Wolfgang Fleischhacker Journal: J Clin Psychiatry Date: 2012-05 Impact factor: 4.384
Authors: T Amano; H Matsubayashi; T Momiyama; K Ishihara; N Todo; M Sasa Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 1995-01 Impact factor: 5.067